Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer by Tagawa, Scott T. et al.
Phase II study of lutetium-177 labeled anti-prostate-specific
membrane antigen (PSMA) monoclonal antibody J591 for
metastatic castration-resistant prostate cancer
Scott T. Tagawa1,2, Matthew I. Milowsky1,3,4, Michael Morris1,4, Shankar Vallabhajosula1,
Paul Christos1,2, Naveed H. Akhtar1, Joseph Osborne1,4, Stanley J. Goldsmith1, Steve
Larson4, Neeta Pandit Taskar4, Howard I. Scher1,4, Neil H. Bander1,2,4, and David M.
Nanus1,2
1Weill Cornell Medical College (WCMC), New York, NY
2Weill Cornell Cancer Center, New York, NY
3University of North Carolina Chapel Hill, North Carolina
4Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
Abstract
Purpose—To assess the efficacy of a single infusion of radiolabeled anti-prostate specific
membrane antigen monoclonal antibody J591 (177Lu-J591) by PSA decline, measurable disease
response, and survival.
Experimental Design—In this dual-center phase II study, 2 cohorts with progressive metastatic
castration-resistant prostate cancer received one dose of 177Lu-J591 (15 patients at 65 mCi/m2, 17
at 70 mCi/m2) with radionuclide imaging. Expansion cohort (n=15) received 70 mCi/m2 to verify
response rate and examine biomarkers.
Results—47 patients who progressed after hormonal therapies (55.3% also received prior
chemotherapy) received 177Lu-J591. 10.6% experienced ≥ 50% decline in PSA, 36.2%
experienced ≥ 30% decline, and 59.6% experienced any PSA decline following their single
treatment. One of 12 with measurable disease experienced a partial radiographic response (8 with
stable disease). Sites of prostate cancer metastases were targeted in 44 of 47 (93.6%) as
determined by planar imaging. All experienced reversible hematologic toxicity with grade 4
thrombocytopenia occurring in 46.8% (29.8% received platelet transfusions) without significant
hemorrhage. 25.5% experienced grade 4 neutropenia with 1 episode of febrile neutropenia. The
phase I maximum tolerated dose (70 mCi/m2) resulted in more 30% PSA declines (46.9% vs
13.3%, p=0.048) and longer survival (21.8 vs 11.9 months, p=0.03), but also more grade 4
hematologic toxicity and platelet transfusions. No serious non-hematologic toxicity occurred.
Those with poor PSMA imaging were less likely to respond.
Conclusion—A single dose of 177Lu-J591 was well-tolerated with reversible myelosuppression.
Accurate tumor targeting and PSA responses were seen with evidence of dose-response. Imaging
biomarkers appear promising.
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INTRODUCTION
Prostate cancer is a radiosensitive disease and radiotherapy is an established form of
definitive treatment for clinically localized prostate cancer and for palliation of painful bone
metastases. Unsealed radiation sources (samarium-153, strontium-89, radium-223) targeting
sites of increased bone metabolism/turnover as an indirect means to target bone metastases
have demonstrated clinical benefit, including decreased pain, some PSA declines, and most
importantly improvement in survival for Ra-223.(1-4) We have investigated the application
of a tumor-targeted monoclonal antibody (mAb) as a means to deliver a cytotoxic payload
directly and specifically to prostate cancer metastases not only in bone, but also soft tissue
and visceral metastases. This approach combines the specificity of mAb targeting with the
tumoricidal effects of beta radiation.
Prostate-specific membrane antigen (PSMA) is a non-secreted cell membrane protein with
expression that is highly restricted to prostate epithelium and upregulated in prostate cancer.
(5-10) Pathology studies indicate that PSMA is expressed by virtually all prostate cancers.
(8, 11-14) PSMA was initially validated as an in vivo target for imaging utilizing
radiolabeled mAb 7E11 (CYT-356, capromab), though therapeutic studies were
disappointing.(15-18) Recognition that PSMA represented a prostate-cancer restricted target
and that 7E11 targets an internal domain and is unable to bind to viable cells led to the
development of mAbs to the exposed, extracellular domain of PSMA.(5,9,19-22) J591, a
deimmunized mAb against the extracellular domain of PSMA is the lead clinical candidate.
(22, 23)
Two independent phase I radioimmunotherapy (RIT) trials have been performed using
Yttrium-90 (90Y) or Lutetium-177 (177Lu) linked via a DOTA chelate to J591 in patients
with metastatic castration-resistant prostate cancer (CRPC).(24, 25) These trials defined the
maximum tolerated dose (MTD), dosimetry, pharmacokinetics, and human anti-humanized
antibody (HAHA) response, and demonstrated preliminary evidence of anti-tumor activity.
177Lu was chosen for further development based upon its physical properties, emitting both
a short-range (0.2-0.3 mm) beta particle as well as gamma emission. As a result, it delivers a
lower radiation dose to bone marrow relative to higher energy beta particles such as 90Y.
(26) The gamma emission from 177Lu allows for ex vivo imaging in contrast to 90Y that, as
a pure beta emitter, requires use of a surrogate isotope such as 111In for imaging. With RIT,
tumor lesion geometry has been proposed to be an important factor and it has similarly been
proposed that the emission characteristics of the isotope should probably be appropriately
matched to the lesion size/volume to be treated to ideally focus energy within the tumor
rather than in the tissue surrounding the lesion/s.(27)177Lu also has a longer physical half-
life (6.7 days compared with 2.7 days for 90Y), resulting in longer tumor residence times.
Because of these properties, higher activities can be delivered using 177Lu; in the phase I
trials of radiolabeled J591, the MTD of 177Lu-J591 was 70 mCi/m2 compared with 17.5
mCi/m2 for 90Y-J591, with lower activity in bone marrow per amount of blood radioactivity.
(24-26) Here we report safety and efficacy data for a phase II study of 177Lu-J591 in patients
with metastatic CRPC.
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Adult subjects with progressive metastatic CRPC were eligible for enrollment. Histologic or
cytologic confirmation of prostate cancer (primary or metastatic site) was required.
Progressive CRPC was defined using modified Prostate Specific Antigen Working Group
(PCWG1) criteria.(28) Continuous LHRH agonist therapy was required for subjects who
had not undergone bilateral orchiectomy. Any number of previous regimens was allowed,
provided the subject had not received anti-PSMA based therapy. Additional inclusion
criteria included ECOG performance status 0 – 2, absolute neutrophil count ≥ 2000/mm3,
platelet count ≥150,000/mm3, serum bilirubin ≤1.5x upper limit of normal (ULN), AST ≤ 2x
ULN, PT/INR and aPTT ≤ 1.3x ULN (unless on anticoagulation) and serum creatinine ≤ 2.5
mg/dL.
Exclusion criteria included prior radiotherapy to > 25% of skeleton, prior 89Strontium
or 153Samarium containing compounds, bone scan demonstrating confluent lesions
involving both axial and appendicular skeleton (“superscan”), other active cancers, or
clinically significant cardiac, renal, hepatic, pulmonary, thyroid, or psychiatric disease.
Concurrent corticosteroids and/or adrenal hormone inhibitors, PC-SPES, finasteride, or
dutasteride were not allowed. This registered study [clinicaltrials.gov NCT00195039] was
approved by the institutional review boards of Weill Cornell Medical College and Memorial
Sloan Kettering Cancer Center and all subjects provided written informed consent.
Treatment
Preparation and quality control of 177Lu-J591 was performed as previously described.(25)
Subjects received a single dose of 177Lu-J591 consisting of J591 chelated at a specific
activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-
DOTA-conjugated (“naked”) J591 to achieve a total antibody dose of 20 mg. Although the
MTD of the phase I dose escalation study was 70 mCi/m2,(25) based upon limited prior
clinical experience with 177Lu-labeled mAbs as directed by the Food and Drug
Administration, an initial cohort of 15 subjects received a dose of 177Lu of 65 mCi/m2
followed by 17 subjects at 70 mCi/m2. After analysis of the initial 32 subjects, an additional
15 were enrolled, underwent infusion of 111In-J591 with subsequent imaging to
prospectively evaluate non-invasive assessment of PSMA expression as a predictive
biomarker, then received a single dose of 177Lu-J591 at 70 mCi/m2. Each dose was
administered without pre-medication by an IV infusion at a rate not to exceed 5 mg/min.
Evaluation During the Study
Subjects were monitored for at least 4 hours post mAb infusion. Complete blood counts
(CBC) were performed at least weekly beginning 3 weeks after 177Lu-J591 infusion until 6
weeks or recovery and were repeated at least twice per week during periods of grade (Gr) 4
neutropenia and at least 3 times per week during periods of Gr 4 thrombocytopenia.
Transfusions, filgrastim or pegfilgrastim (but not sargramostim), and red blood cell growth
factors were permitted at the discretion of the treating physician. Chemistry panel including
liver tests and PSA was performed at least every 4 weeks. Expansion cohort subjects had a
baseline circulating tumor cell (CTC) count by CellSearch (Veridex) methodology at
baseline and 4-6 weeks following 177Lu-J591 infusion.
A planar gamma camera image was obtained 5-7 days after 177Lu-J591 infusion (expansion
cohort subjects also had pre-treatment imaging 3-4 days after 111In-J591 infusion) with
SPECT images obtained in selected patients. Radiolabeled J591 images were compared to
baseline clinical bone scintigraphy and cross sectional imaging. After planar gamma camera
imaging, images were scored using 2 methods. A five point visual scale was performed by
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two independent radiologists and scored 0 (no uptake), 1 (weakly positive), 2 (definitely
positive), 3 (equal intensity to liver), 4 (greater uptake than liver). Tumor Targeting Index
(TuTI), a novel metric designed to semi-quantitatively score images was calculated for the
most prominent lesions in each subject using the ratio of lesion count density (corrected for
background) to whole body count density. TuTI = (lesion ROI count density – background
count density)/(total body count density). Assessment of accurate uptake of radiolabeled
mAb by known sites of disease was performed comparing visual scores and TuTI to areas of
known metastatic disease on bone scan and CT/MRI. CT or MRI of abdomen/pelvis and
bone scans were repeated 3 months after 177Lu-J591 infusion and every 3 months thereafter
until progression. Radiographically measurable disease was defined as lymph nodes of at
least 20 mm and non-osseous visceral disease of at least 10 mm in greatest diameter.
Statistical Plan
The primary endpoint of the study was response rate, evaluated by the measurable-disease
response rate and post-treatment PSA decline rate, which was originally defined as the
percent of patients who achieved a ≥50% decrease in PSA from baseline without
requirement for confirmation. With an initial sample size of 32 patients, a two-sided 95%
confidence interval (CI) for the response proportion was estimated to extend 0.10 from the
observed proportion for an expected proportion of 10%. For an expected proportion of 15%,
the CI was estimated to extend 0.12 from the observed proportion. The expansion cohort to
bring the 70 mCi/m2 dose to 32 subjects allowed a two-sided 95% CI to be constructed to be
within ± 11% of the expected ≥50% PSA decline response rate. A ≥30% response rate was
added to the primary endpoint as an amendment based upon the survival association in
chemotherapy trials published after this study began (29, 30) and a retrospective analysis of
radiolabeled-J591 studies with a similar survival association; the 32 subjects allowed a 2-
sided CI within ± 17% of the expected ≥30% PSA decline response rate. Kaplan-Meier
survival analysis was used to estimate overall survival (OS), with median OS and 95% CI’s
described. Descriptive statistics were performed to characterize the study sample.
Based upon observations made after study initiation, additional analyses were performed in
post hoc fashion in the initial cohorts and prospectively in the expansion cohort. Fisher’s
exact test was used to compare ≥30% PSA decline response proportions between the 65
mCi/m2 and 70 mCi/m2 dose cohorts and between quartiles of mean TuTI. The log-rank test
was employed to compare OS between the two dose cohorts and between levels of PSA
decline (≥30% vs <30% PSA decline). Median OS and 95% confidence intervals for median
OS were stratified by dose cohort and level of PSA decline. All p-values are two-sided with
statistical significance evaluated at the 0.05 alpha level. All analyses were performed in SAS
Version 9.2 (SAS Institute, Inc., Cary, NC) and STATA Version 11.0 (StataCorp, College
Station, TX).
RESULTS
In the initial portion of the trial, 32 subjects were treated between November, 2004 and
February, 2008 at 2 centers; 15 additional subjects were treated in the expansion cohort
between June 2009 and February 2012. Baseline demographics including prognostic
variables are summarized in Table 1. All had progressed on multiple lines of hormonal
therapy and the majority (55.3%) progressed on 1-4 lines of chemotherapy including
docetaxel. There were no significant differences in any demographic or prognostic variables
between the cohorts.
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Anti-tumor Effects and Survival
All subjects had progression by PSA prior to enrollment. Overall, five patients (10.6%; 95%
CI=2.0-25.0%) experienced ≥ 50% decline in PSA from baseline, seventeen (36.2%)
experienced ≥ 30% decline, and twenty eight (59.6%) experienced any PSA decline with
median time to progression of 12 weeks (range 8-47 weeks) following their single treatment.
Each subject’s best PSA response is depicted in Figure 1. Although the study was initially
designed to have both cohorts analyzed together, a suggestion of dose-response was
observed in favor of the 70 mCi/m2 cohort (the phase I MTD),(25) leading to the expansion
cohort, confirming the dose-response relationship as depicted in Table 2, with 46.9% vs
13.3% with ≥30% PSA decline (p=0.048).(Individual PSA changes by dose received is
depicted in Supplemental Figure 1A) Twelve of the 15 patients in cohort 3 had CTC counts
measured at baseline and at 4-6 weeks following treatment (2 lab failures and 1 missed
blood draw); 8 (66.7%) had ≥50% decline in CTC counts and 3 (25%) were unchanged at 0
or 1 per 7.5 mL blood (1 declined 27%).(Supplemental Figure 1B)
Only twelve (25.5%) patients had measurable disease; 1 experienced a partial response by
RECIST(31) with confirmed 55% decrease in nodal metastases, 8 had stable disease, 2 with
progressive disease, and 1 was lost to follow up prior to repeat image (with PSA increase of
10% from baseline at last evaluation).(Supplemental Figure 1C)
Median overall survival (OS) for all patients was 17.6 months (95% CI = 15.2, 20 months),
with improved survival for the 70 mCi/m2 cohort as compared with the 65 mCi/m2 cohort
(median OS = 21.8 months [95% CI = 16.3, 27.3 months] vs. 11.9 months [95% CI = 6.5,
17.3 months], respectively, P= 0.03) (Figure 2). As only a minority of patients had
measurable disease, therapies with potential immune mechanisms may provide survival
benefits independent of immediate response, and we had adequate follow up for survival
analysis, we explored relationships between dose, PSA changes, and survival. In the overall
study (all 3 cohorts), median OS for those with any PSA decline was 22.2 months [18.6,
25.7] compared to 11.4 months [8.4, 14.4] for those without PSA decline (P<0.01). The 17
patients with ≥ 30% PSA decline had a median OS of 22.2 months (95% CI = 18.4, 25.9
months) compared to 15.7 months (95% CI = 10.2, 21.3 months) among those with less than
a 30% PSA decline (P=0.06).
Imaging
Planar gamma camera imaging was performed on all patients. Forty four subjects (93.6%)
had accurate targeting of known sites of disease when compared to baseline CT/MRI and
bone scan images, though those with liver metastases were difficult to assess because of the
antibody’s partial hepatic clearance (Figure 3). As our initial imaging data suggested
significant variability of PSMA expression levels across the patient population, we therefore
retrospectively explored the correlation between TuTI and PSA response in the initial
cohorts. In the lowest quartile of mean TuTI’s (i.e. those with lowest PSMA expression by
imaging), 12.5% experienced ≥ 30% PSA decline (0% with >50% decline), whereas in the 3
remaining quartiles 37.5% experienced ≥ 30% PSA decline (8.3% with >50% decline)
(p=0.19). Prospective evaluation of this association using 111In-J591 imaging prior to 177Lu-
J591 treatment in cohort 3 demonstrate the same trend (p=0.19). No association between
imaging and toxicity was seen.
Toxicity
Without pre-medication, 11 subjects (23.4%) experienced transient, reversible infusion
reactions consisting of feelings of warmth (with or without temperature changes), cold
(without episodes of hypothermia), flushing, rigors, or elevation of blood pressure. All
completed drug infusion and four (8.5%) received pharmacologic intervention
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(diphenhydramine and/or acetaminophen; 2 received meperidine). Eight (17%) experienced
transient grade (Gr) 1 transaminase elevation; 2 with Gr 2 (1 of whom had Gr 1 elevation at
baseline). Treatment emergent adverse events are summarized in Table 3.
All experienced hematologic toxicity, with nadir platelet and neutrophil counts occurring at
a median of 4 weeks after 177Lu-J591 administration. Grade 4 thrombocytopenia occurred in
22 (46.8%) lasting a median of 7 (range 3-17) days; 14 received platelet transfusions
(median 2, range 1-4 transfusions). None experienced significant hemorrhagic episodes.
Three had Gr 1 ecchymosis at blood draw or other traumatic sites. Thirty nine (82.9%)
experienced complete (i.e. at least 150,000/mcL) platelet recovery within a median of 25
days. Seven experienced recovery to Gr 1 (range 118-130,000/mcL peak platelet counts).
One recovered to only grade 2 (59,000/mcL). Of those with incomplete recovery, all had
concurrent progressive disease by PSA. Three who experienced partial platelet count
recovery (i.e. increase from nadir) and subsequent decline had concurrent PSA rises and
significant prostate cancer infiltration of bone marrow with otherwise normal hematopoietic
elements on bone marrow biopsy. Twelve (25.5%) experienced Gr 4 neutropenia up to 17
days in duration (median 5, range 2-17 days); 1 had febrile neutropenia. Nine patients
(19.1%) received filgrastim or pegfilgrastim. Hematologic toxicity was greater in the 70
mCi/m2 cohort (Table 2), with significantly more platelet transfusions and grade 4
neutropenia. No correlation between toxicity and sites of disease or number of bone
metastases was observed, though there was a trend for more platelet transfusions in those
who previously received radiotherapy (p=0.15 in univariate analysis, p=0.25 when
correcting for 177Lu dose) and for those with lower baseline platelet counts (p=0.11). There
was no difference in Gr 4 neutropenia with previous chemo- or radiotherapy.
DISCUSSION
Although RIT was first studied in solid tumors, the largest experience with RIT to date
involves targeting the CD20 antigen (131I tositumomab or 90Y ibritumomab tiuxetan) in
non-Hodgkin’s lymphoma. Radioimmunotherapy for solid tumors has lagged behind for
several reasons, including a dearth of antigens of adequate tumor-specificity and concerns
regarding tumor radio-resistance and antibody penetration. Other practical reasons have
included difficulties in stably linking radionuclides to existing mAbs, shortfalls in existing
(and readily available) radionuclides, and difficulty in clinical use (coordination between
different specialties).(32) Prostate cancer is not subject to these limitations: (i) a highly
tumor-restricted antigen, PSMA, has been identified; (ii) PC is radiosensitive; and (iii)
metastatic PC can be identified at the stage of small volume lesions in bone marrow and
lymph nodes that are well accessed by circulating antibody.
Radiation therapy may be delivered to primary and secondary sites of prostate cancer for
curative or palliative intent via external beam or brachytherapy. Systemic radioisotope
therapy targeting bone has also been successfully utilized. Samarium-153 and Strontium-89
are approved β-emitting agents for palliation of painful bony metastases.(1-4) Recently, an
α-emitting agent has demonstrated a survival benefit in men with metastatic CRPC to bone.
(4, 33) While bone-seeking radiopharmaceuticals may be seen as targeted agents with
proven efficacy, they do not target tumor directly. Rather, their anti-tumor effect derives
from radiopharmaceutical accumulation in proximity to malignant cells and/or stroma; these
agents entirely ignore soft tissue and extra-osseous visceral metastases.
“Targeted” therapeutics offer a potential advantage in cancer therapy by sparing normal
tissues. In prostate cancer, PSMA is an ideal target, as it is highly over-expressed by
virtually all prostate cancers, and not significantly expressed by normal cells. The few sites
that do express low levels of PSMA (e.g. renal proximal tubule lumen and brush border of
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small intestine) have minimal exposure to anti-PSMA mAb-based therapy, as these sites are
not accessible to circulating intact mAb. In addition, recent therapeutic advances in targeting
the AR-axis lead to increased PSMA expression.(34) We demonstrated safety and accurate
tumor-targeting in previous studies using trace-labeled J591 in patients with advanced PC,
but responses to the unarmed antibody in this patient population were limited.(22) These
studies led to anti-PSMA-based RIT studies utilizing β- emitting radionuclides. Two phase I
studies in patients with metastatic CRPC formed the basis for the current study.(24, 25)
While a few efficacy studies have utilized mAbs against non-tumor-specific targets alone or
in combination in solid tumor RIT,(35-40) this trial represents one of the few reported phase
II studies of disease-specific single-agent RIT (i.e. targeted radiotherapy utilizing a disease-
specific mAb) with mature follow up in solid tumor oncology.(41)
In this study, we successfully targeted known sites of metastatic disease in 93.6% of
unselected metastatic CRPC subjects, confirming our previous results. More importantly, the
initial evidence of anti-tumor efficacy observed in the phase I studies was supported,(24, 25)
with the majority of subjects demonstrating PSA declines. Though PSA changes have never
fully met criteria for surrogate endpoints, it is important to note that unlike other therapies
including docetaxel,(42-44) J591 has no direct effect on PSA transcription, expression or
secretion [NHB, unpublished data], PSA declines vs. increases following radiolabeled J591
therapy have been associated with radiographic response or progression,(24) and the data
from this study as well as retrospective analysis of other radiolabeled J591 studies,(45)
though preliminary, would suggest that patients with PSA declines lived significantly longer
(P=0.01).
Numerous publications evaluating PSMA expression have indicated that 84-100% of
prostate cancers are PSMA-positive.(8, 11-14) Therefore, patient selection based on PSMA
expression was not performed in this study. Even though receptor sites are not saturated, it
has been shown that the amount of radiolabeled mAb uptake is proportionate to the level of
antigen expression;(46) it is logical that the level of PSMA expression might correlate with
response to PSMA-targeted therapy and provide a predictive parameter to identify those less
likely to respond (i.e. those with no or low PSMA expression). Post-hoc analysis of the
initial cohorts suggested imaging-based scoring of PSMA expression may correlate with
subsequent response. Since using 177Lu-J591 as the imaging agent carries the toxicity
associated with beta-emission, we performed a pre-treatment scan utilizing 111In-J591 in the
prospective cohort, demonstrating the same trend for a lower likelihood of response for
poor-imagers. However, planar or even SPECT imaging, is qualitative by nature which may
limit clinical utility. Use of quantitative imaging, such as anti-PSMA-based positron
emission tomography (PET),(34,47) may be more effective in selecting the best candidates
(or more practically ruling out poor candidates given general expression levels) for a PSMA-
targeted therapeutic.
As described in the methods section, initial plans were for a single-arm phase II study at the
phase I MTD / recommended phase II dose (70 mCi/m2). Based upon limited prior
experience with 177Lu and discussions with the FDA, a cohort treated at a slightly lower
dose (65 mCi/m2) was used with the expectation that neither efficacy nor toxicity would be
significantly different. In the initial cohorts, we observed preliminary evidence suggestive of
a dose-response relationship which led to an expansion cohort which validated the increased
PSA response rates seen with a single infusion of 70 mCi/m2 of 177Lu-J591; this group also
experienced improved survival.
In RIT clinical trials, factors such as antibody internalization and the physical properties of
the radionuclide, including the type of particle(s) emitted, half-life, and path-length are
important in designing the appropriate clinical strategy.(27, 48) Whereas PSMA/J591 is an
Tagawa et al. Page 7













excellent antigen/antibody pair in PC, the physical properties of 177Lu theoretically make it
most optimal for patients with micro-metastatic disease. Consequently, the patients treated
in this phase II trial may be a less suitable cohort in which to demonstrate durable responses.
The observed anti-tumor activity together with the additional safety data suggest that 177Lu-
J591 targeted radiotherapy may be safe and effective in PC patients with micro-metastatic
disease. A multi-institutional trial has begun to test this hypothesis (clinicaltrials.gov
NCT00859781) and pre-clinical work is ongoing on J591-alpha particle emitters.
One concern related to RIT is the possibility that treatment may result in damaged bone
marrow that might prevent patients from receiving subsequent therapy. The dose-limiting
toxicity of RIT in general is transient myelosuppression, which typically occurs in a delayed
fashion compared to cytotoxic chemotherapy.(49) Myelodysplastic syndrome and acute
leukemia have been reported with anti-CD20 based RIT for non-Hodgkin’s lymphoma,(50)
though larger studies have not substantiated this effect.(51, 52) In this study all subjects
were treated at or near the MTD (i.e. at or near a dose leading to significant
myelosuppression). While all subjects recovered normal neutrophil counts, 7 did not fully
recover a normal platelet count. This effect cannot be attributed solely to the radioisotope
however, because all of these subjects had clinically progressive prostate cancer and the 3
who underwent bone marrow biopsy revealed infiltrative metastases, so it is plausible that
their lack of complete recovery was secondary to progression of their prostate cancer. As
with patients receiving chemotherapy, not all have full recovery of blood counts as
evidenced by the patients treated on recent post-chemotherapy studies with baseline and
ongoing thrombocytopenia post-docetaxel.(53, 54) In preliminary review of our overall anti-
PSMA-based RIT experience through 2009 (109 patients), excluding re-treated patients,
98% and 87% had full recovery of neutrophils and platelets respectively.(55) Of the
remaining, all but 4 recovered to Gr 1 neutropenia and/or thrombocytopenia. The most
common reason for lack of complete hematologic recovery was CRPC progression (PSA
and or scan progression with confirmatory bone marrow biopsy revealing significant
prostate cancer metastases). No cases of post-RIT myelodysplasia and/or leukemia have
been observed.(55)
In summary, a single dose of 177Lu-J591 was well-tolerated with reversible
myelosuppression. PSA responses were seen with evidence of a 177Lu dose-response
relationship. This study further validates PSMA as an excellent PC-restricted target as well
as the performance of the J591 antibody in vivo. The anti-tumor activity seen suggests
clinical potential of targeting other types of cytotoxic agents to PSMA. Future directions in
progress with anti-PSMA RIT include i) studies to improve patient selection utilizing
imaging and CTC and immunohistochemical PSMA-expression analysis, ii) improving
therapeutic margin with dose-fractionation, (23, 56) iii) utilizing taxane radiosensitization
and tumor debulking (combination studies),(23, 57) and iv) “targeted salvage radiotherapy”
exploring 177Lu-J591 in the biochemically recurrent population, a setting in which the
physical properties of 177Lu should be more optimally suited.(23,58,59) In addition, a
randomized phase III registration trial in men with metastatic CRPC is planned.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Targeted therapies are of relevance to many fields of medicine. Prostate specific
membrane antigen (PSMA) represents a highly restricted, over-expressed prostatecancer
cell-surface protein. J591, a de-immunized monoclonal antibody targeting the external
domain of PSMA has been successfully radiolabeled with β-emitting radionuclides. Here,
we report a phase II trial of a single dose of 177Lu-J591 that successfully targets known
sites of disease in men with progressive metastatic, castration-resistant prostate cancer.
Declines in prostate specific antigen were demonstrated, with a dose-response
relationship seen. Circulating tumor cell count control occurred in the majority of
patients tested. Non-invasive assessment of PSMA expression via imaging may prove to
be a predictive biomarker. Based upon this and other clinical trials plus the physical
properties of 177Lu (short path length), a randomized study is ongoing targeting a
theoretically more optimal micro-metastatic disease opulation (i.e. castration-resistant
prostate cancer without metastases) and a phase III registration trial is planned.
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Each individual subject’s best PSA response on study. Those subjects treated with 65 mCi/
m2 of 177Lu-J591 (Cohort 1) are indicated in light gray while those that received 70 mCi/m2
of 177Lu-J591 (the phase I trial maximum tolerated dose) are indicated in blue (Cohort 2) or
red (Cohort 3).
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Probability of survival by dose received. [OS:overall survival; mo: months]
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Left: 99mTc-MDP bone scan: Anterior (A) and posterior (B) images of pretreatment bony
metastases. Right: 177Lu-J591 scan: Anterior (C) and posterior (D) total body images
obtained via dual head gamma camera of sites of uptake 7 days after 177Lu-J591
administration. (Note: Radiolabeled antibody is partially cleared via the liver resulting in
non-specific 177Lu localization).
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 Bone 46 (97.9%)
 Lymph Node 28 (59.6%)
 Lung 11 (23.4%)
 Liver 4 (8.4%)
 Other 3 (6.4%)
ECOG Performance Status
 0 13 (27.7%)




 Range 134 - 647
Hemoglobin
 Median 11.9
 Range 9.8 - 14.1
Alkaline Phosphatase
 Median 99
 Range 23 - 1170
CALGB Prognostic Score (60)
 Median 149
 Range 88 - 184
# Previous Hormonal Therapies
 1 6 (12.7%)
 2 21 (44.6%)
 3 14 (29.8%)
 4 6 (12.7%)
# Previous Chemotherapy Regimens
 0 21 (44.6%)
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 1 19 (40.4%)
 ≥ 2 7 (14.9%)
Prior Radiation
 Prostate / Prostate bed 21 (44.7%)
 Palliative to bone metastasis 3 (6.4%)
 Other* 1 (2.1%)
*
Other: 1 subject received prior investigational radioimmunotherapy
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Table 3
Treatment emergent adverse events
CTCAE Toxicity Grade 1-2 Grade 3 Grade 4 Total
Non-Hematologic
 ALT (SGPT) 6 (12.8%) 6 (12.8%)
 Anorexia 11 (23.4%) 11 (23.4%)
 AST (SGOT) 9 (19.2%) 9 (19.2%)
 Bruising (without thrombocytopenia) 2 (4.3%) 2 (4.3%)
 Constipation 5 (10.6%) 5 (10.6%)
 Creatinine 5 (10.6%) 5 (10.6%)
 Diarrhea 4 (8.5%) 4 (8.5%)
 Dizziness 1 (2.1%) 1 (2.1%)
 Dyspepsia 2 (4.3%) 2 (4.3%)
 Dyspnea 3 (6.4%) 3 (6.4%)
 Edema: limb 1 (2.1%) 1 (2.1%)
 Fatigue 17 (36.2%) 17 (36.2%)
 Fever (without neutropenia) 1 (2.1%) 1 (2.1%)
 Hemorrhage, GI: Oral cavity 1 (2.1%) 1 (2.1%)
 Hypersensitivity (aka Infusion Reaction) 11 (23.4%) 11 (23.4%)
 Nausea 5 (10.6%) 5 (10.6%)
 Pain - Abdomen NOS 2 (4.3%) 2 (4.3%)
 Pain - Joint 1 (2.1%) 1 (2.1%)
 Petechiae/purpura 1 (2.1%) 1 (2.1%)
 Rash/desquamation 1 (2.1%) 1 (2.1%)
 Rigors/chills 1 (2.1%) 1 (2.1%)
 Taste alteration (dysgeusia) 1 (2.1%) 1 (2.1%)
 Weight Loss 1 (2.1%) 1 (2.1%)
Hematologic (see Table 2 for dose comparisons)
 Hemoglobin 19 (40.1%) 5 (10.6%) 24 (51.1%)
 Leukocytes (total WBC) 14 (29.8%) 22 (46.8%) 4 (8.5%) 40 (85.1%)
 Neutrophils (ANC) 7 (14.9%) 17 (36.2%) 12 (25.5%) 36 (76.6%)
  Febrile neutropenia 1 (2.1%) 1 (2.1%)
 Platelets 4 (8.5%) 10 (21.3%) 22 (46.8%) 36 (76.6%)
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